Stock Info (+) Info bourse (+)

TSX: SVA  |  OTCQB: SEOVF

The Path to a Regenerative Cure Le chemin vers un traitement régénérateur

The Path to a Regenerative Cure Le chemin vers un traitement régénérateur

Sernova is a regenerative medicine therapeutics company Sernova est une société de traitement en médecine régénérative

Developing therapeutics platform technologies to treat chronic diseases through a regenerative medicine approach. Sernova’s primary focus is the development of technologies for the treatment of patients with insulin-dependent (T1) diabetes, hemophilia A and thyroid disease. Développer des technologies de plate-forme thérapeutique pour traiter les maladies chroniques grâce à une approche de médecine régénérative. L’objectif principal de Sernova est la mise au point de technologies de traitement du diabète insulino-dépendant (T1), de l’hémophilie A et de la thyroïde.

About Sernova, Corp. À propos de Sernova, Corp.

Sernova is committed to the development and clinical advancement of its products for metabolic, hematological and other chronic diseases using therapeutic cells transplanted into a patented implanted medical device, which forms an organ-like environment promoting long-term function and survival of the therapeutic cells. Sernova s'engage dans le développement et l'avancement clinique de ses produits contre les maladies métaboliques, hématologiques et autres maladies chroniques utilisant des cellules thérapeutiques transplantées dans un dispositif médical implanté breveté, qui forme un environnement semblable à un organe favorisant la fonction et la survie à long terme des cellules thérapeutiques.

The company’s management believes in building strong and long-lasting collaborations and partnerships that would lead to the rapid advancement of Sernova’s portfolio of products into the market, improving global health and bringing value to patients and society, in concert with our clinical development programs. La direction de la société croit à la mise en place de collaborations et de partenariats solides et durables qui permettraient au portefeuille de produits de Sernova de progresser rapidement sur le marché, d’améliorer la santé mondiale et d’apporter une valeur ajoutée aux patients et à la société, de concert avec nos programmes de développement clinique.

Indications: Les indications:


Diabetes Diabète

Haemophilia A Hémophilie A

Thyroid disease Maladie thyroïdienne

Clinical studies: Etudes cliniques:


Diabetes US phase I/II clinical study cleared by the FDA Etude clinique de phase I / II sur le diabète, approuvée par la FDA

First-in-human study in Diabetic subjects with hypoglycemia unawareness Première étude chez l'homme chez des sujets diabétiques peu conscients de l'hypoglycémie

Cell Pouch System™


Sernova’s Cell Pouch System™ is a novel implantable and scalable medical device which forms a highly vascularized organ-like environment in the body for the housing, function and long-term survival of therapeutic cells. These therapeutic cells release necessary proteins or hormones missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Le Cell Pouch System™ est un nouveau dispositif médical préalablement implanté et formant un environnement naturel hautement vascularisé afin d’y loger des cellules thérapeutiques, favorisant leur bon fonctionnement et leur survie dans le corps. Ces cellules thérapeutiques libèrent les protéines ou les hormones nécessaires pour traiter les maladies chroniques comme alternative a l’administration quotidienne de médicaments.


Immune Protection Protection immunitaire


We have shown that cells can be protected using medications that prevent immune system attack within the Cell Pouch™. Nous avons montré que les cellules peuvent être protégées en utilisant des médicaments qui empêchent les attaques du système immunitaire dans la Cell Pouch™.

Microencapsulation technologies house cells within the Cell Pouch chambers and protect the cells from immune system attack. Les technologies de microencapsulation hébergent les cellules dans les chambres à cellules et les protègent des attaques du système immunitaire.

Technologies are in development to make transplanted cells unrecognizable to the immune system. Des technologies sont en cours de développement pour rendre les cellules greffées méconnaissables du système immunitaire.

Sernova’s Cell Pouch™, combined with immune protected therapeutic cells, offers protection from immune system attack creating an effective, safe, long-term and convenient therapeutic option for patients with chronic diseases who seek to improve their quality of life. Le Cell Pouch™ de Sernova, associé à des cellules immunitaires protégées, offre une protection contre le système immunitaire avec une option thérapeutique efficace, sûre, à long terme et pratique pour les patients atteints de maladies chroniques qui cherchent à améliorer leur qualité de vie.


Featured News Nouvelles en vedette

June 2, 2022 2 June, 2022

Loading... Chargement...

Sernova Opens the Market Thursday, June 2, 2022

February 25, 2022 25 February, 2022

Loading... Chargement...

Sernova Made the 2022 TSX Venture 50 List!

November 18, 2021 18 November, 2021

Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

September 30, 2021 30 September, 2021

Loading... Chargement...

Dr. Tomei Conformal Coating Immunoprotection Webinar with Sernova

July 6, 2021 6 July, 2021

Sernova 2021 AGM Recording

April 28, 2021 28 April, 2021

Loading... Chargement...

Sernova KOL Event on Thyroid Disease with Dr. Sam Wiseman


News Releases Communiqués de presse

June 15, 2022 15 June, 2022

Sernova to Participate in the Truist Securities Cell Therapy Symposium, Symposia-cel in June

June 6, 2022 6 June, 2022

Sernova Announces Positive Updated Phase 1/2 Clinical Data on Cell Pouch System™ at American Diabetes Association 82nd Scientific Sessions 2022

June 1, 2022 1 June, 2022

SERNOVA SHARES TO COMMENCE TRADING ON TSX ON JUNE 2, 2022

May 24, 2022 24 May, 2022

Sernova Receives Conditional Approval to Up-list to the Toronto Stock Exchange

Invest with Sernova Investir dans Sernova

If you are a shareholder, investor, broker, analyst, journalist, investment advisor, or looking to develop business opportunities, please feel free to contact us by email or telephone. Si vous êtes actionnaire, investisseur, courtier, analyste, journaliste, conseiller en placement ou souhaitez développer des opportunités d’affaires, n'hésitez pas à nous contacter par email ou par téléphone.

Sernova is a regenerative medicine company developing therapeutic technologies with multibillion-dollar market potential for each of its clinical indications. Sernova est une société de médecine régénérative développant des technologies thérapeutiques offrant un potentiel de marché de plusieurs milliards de dollars pour chacune de ses indications cliniques.

 

Diabetes patients Patients diabétiques

 

Hemophilia Orphan Indication Indication orpheline de l'hémophilie

 

Sernova is traded on: Sernova est échangé sur:

Subscribe to our Newsletter Abonnez-vous à notre newsletter

*indicates required* requis

By subscribing to our Newsletter you will receive Sernova’s press releases and news as they develop by email. We do not send direct mail, customized online advertising, and we do not share your personal information. We respect your privacy. En vous abonnant à notre newsletter, vous recevrez par e-mail les communiqués de presse et les actualités de Sernova au fur et à mesure de leur développement. Nous n'envoyons pas de publipostage, de publicité en ligne personnalisée et nous ne partageons pas vos informations personnelles. Nous respectons votre vie privée.

Please read our Pour plus d’informations, veuillez lire notre Privacy policypolitique de confidentialité.

Sernova is a Collaborative Team Sernova, c’est aussi les collaborations

We believe in advancing our clinical programs and building strong and long-lasting collaborations and partnerships that will lead to the rapid advancement of Sernova’s portfolio of products into the market, improving global health and bringing value to patients and society. Nous croyons en la promotion de nos programmes cliniques et en la mise en place de collaborations et de partenariats solides et durables qui permettront au portefeuille de produits de Sernova de progresser rapidement sur le marché, d'améliorer la santé mondiale et d'apporter de la valeur aux patients et à la société.

 

Privacy PolicyPolitique de confidentialité

Updated July 6, 2018

Please read this Policy carefully along with our Legal Notice that describes our Terms of Use for the Website.

By accessing www.sernova.com (the “Website”) you hereby agree with the practices described in this Privacy Policy (the “Policy”)

This Policy applies to all information gathered through the Website and/or any related marketing technique or events.



Information Collection

The information collected is limited to the information that you decide to share with us through the News Dispatch Service, when participating at event or activities or in the general course of business by expressing an interest in obtaining information about Sernova Corp. and our products, such as name, email, phone number, and similar contact information. This information is stored through MailChimp (please refer to MailChimp Privacy Policy at https://mailchimp.com/legal/privacy/).



Information Sharing

Sernova Corp. is the sole owner of any information collected on the Website. We do not sell, share or rent this information to others.



Traffic and Automatic Information Collection

Sernova Corp. maintains log files of the traffic on www.sernova.com. This information is not linked to any personal information that you have provided us. Logs are used to manage traffic, identify content accessed, and IT requirements. Information logged and automatically collected includes without being limited to IP addresses and browser types. This information does not reveal your specific identity.



Cookies

Cookies can be used to provide you with a more personalized experience. The Website may use cookies to make that experience more companionable when you return to the Website. You have the option at all time to decline the use of cookies. If you choose to do so, you may not be able to fully use all features of the Website. You can also delete cookie files at all time from your computer. Those cookies may include first-party cookies (such as the Google Analytics cookies).



Updates

This Policy is a living document and may be amended or updated from time to time without further notice. We encourage you to review the Policy periodically.



Contact

If you have any questions or comments about our policy, you can email us at info@sernova.com or by phone at 1(877) 299-4603 or by mail at

Sernova Corp.
700 Collip Circle, Suite 114
London, ON Canada N6G 4X8

Mis à jour le 6 juillet 2018

Veuillez lire attentivement cette politique ainsi que notre avis juridique qui décrit nos conditions d'utilisation du site Web.

En accédant à www.sernova.com (le «site Web»), vous acceptez les pratiques décrites dans la présente politique de confidentialité (la «politique»).

Cette politique s'applique à toutes les informations collectées via le site Web et / ou toute technique ou événement marketing associé.



Collecte d'informations

Les informations collectées se limitent aux informations que vous décidez de partager avec nous par le biais du service d’expédition de nouvelles, lorsque vous participez à un événement ou à des activités ou que vous vous intéressez à obtenir des informations sur Sernova Corp. comme nom, email, numéro de téléphone et informations de contact similaires. Ces informations sont stockées via MailChimp (veuillez vous reporter aux règles de confidentialité de MailChimp sur https://mailchimp.com/legal/privacy/).



Partage d'information

Sernova Corp. est l'unique propriétaire de toute information collectée sur le site Web. Nous ne vendons pas, ne partageons pas ou ne louons pas ces informations à des tiers.



Collecte d'informations routières et automatiques

Sernova Corp. gère les fichiers journaux du trafic sur www.sernova.com. Ces informations ne sont liées à aucune information personnelle que vous nous avez fournie. Les journaux sont utilisés pour gérer le trafic, identifier le contenu accédé et les besoins informatiques. Les informations consignées et collectées automatiquement ne sont pas limitées aux adresses IP et aux types de navigateur. Cette information ne révèle pas votre identité spécifique.



Cookies

Les cookies peuvent être utilisés pour vous offrir une expérience plus personnalisée. Le site Web peut utiliser des cookies pour rendre cette expérience plus conviviale lorsque vous revenez sur le site Web. Vous avez la possibilité à tout moment de refuser l'utilisation de cookies. Si vous choisissez de le faire, vous ne pourrez peut-être pas utiliser toutes les fonctionnalités du site Web. Vous pouvez également supprimer des fichiers de cookies à tout moment depuis votre ordinateur. Ces cookies peuvent inclure des cookies de première partie (tels que les cookies de Google Analytics).



Mises à jour

Cette politique est un document évolutif et peut être modifié ou mis à jour de temps à autre sans préavis. Nous vous encourageons à consulter la politique périodiquement.



Contact

Si vous avez des questions ou des commentaires sur notre politique, vous pouvez nous envoyer un courriel à info@sernova.com ou par téléphone au 1 (877) 299-4603 ou par courrier à

Sernova Corp.
700 Collip Circle, Suite 114
London, ON Canada N6G 4X8

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - June 15, 2022 15 June, 2022

Sernova to Participate in the Truist Securities Cell Therapy Symposium, Symposia-cel in June


LONDON, Ontario – June 15, 2022 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical- stage company and leader in regenerative medicine cell therapeutics, today announced that Dr. Philip Toleikis, President & CEO of Sernova Corp., will be participating in the Truist Securities Cell Therapy Symposium, Symposia-cel being held in person at the Lotte New York Palace on Tuesday, June 28, 2022. Company management will also be participating in 1x1 meetings during the event.

Truist Securities Cell Therapy Symposium, Symposia-cel – June 28, 2022 Panel Title: Cell Therapy for Non-Oncology Indications Date: Tuesday, June 28, 2022 Time: 2:00-3:00 PM ET Presenter: Dr. Philip Toleikis, President & CEO, Sernova Corp Location: Lotte New York Palace* * Further details available on the Truist event website

If you are interested in arranging a 1x1 meeting request, please contact your Truist representative.

ABOUT SERNOVA CORP. AND THE CELL POUCH SYSTEM™ PLATFORM FOR CELL THERAPY

Sernova Corp. is a clinical-stage biotechnology company that is developing regenerative medicine therapeutic technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders including hemophilia A. Sernova is currently focused on developing a ‘functional cure’ for insulin-dependent diabetes with its lead asset, the Cell-Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch on implantation forms a natural vascularized tissue environment in the body for long-term survival and function of therapeutic cells that release necessary proteins or factors missing from the body to treat chronic diseases. Sernova’s Cell Pouch System has already shown it can potentially provide a ‘functional cure’ to people with type 1 diabetes in an ongoing Phase I/II clinical study at the University of Chicago. Sernova is also advancing a proprietary technology in collaboration with the University of Miami to cloak the therapeutic cells from the immune system attack with the goal to eliminate the need for chronic immunosuppressives. In May 2022, Sernova and Evotec entered into a global strategic partnership to develop an implantable off-the-shelf iPSC-based (induced pluripotent stem cells) beta cell replacement therapy. This partnership provides Sernova an unlimited supply of insulin-producing cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2). Sernova is also gearing up to be in the clinic in two additional programs that utilize its Cell Pouch System – an implantable cell therapy for benign thyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral factor 8 gene therapy for hemophilia A.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Corporate: Christopher Barnes VP, Investor Relations Sernova Corp. christopher.barnes@sernova.com 519-902-7923 www.sernova.com

Investors: Corey Davis, Ph.D. LifeSci Advisors, LLC cdavis@lifesciadvisors.com 212-915-2577

Media: Elizabeth Miller, M.D. LifeSci Communications emiller@lifescicomms.com

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - June 06, 2022 6 June, 2022

Sernova Announces Positive Updated Phase 1/2 Clinical Data on Cell Pouch System™ at American Diabetes Association 82nd Scientific Sessions 2022


• Researchers from the Dr. Piotr Witkowski Laboratory at the University of Chicago presented updated data on six patients with type 1 diabetes and hypoglycemia unawareness • The first three patients have been insulin independent for over 2 years, 6 months, and 3 months, respectively • Those first three patients with islets transplanted into the Cell Pouch™ subsequently presented positive serum C-peptide values confirming active insulin production by the Cell Pouch islet grafts • The Cell Pouch was well tolerated with implant durations exceeding 35 months

LONDON, Ontario – June 6, 2022 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical- stage company and leader in regenerative medicine cell therapeutics, today announced the presentation of clinical data from its Phase 1/2 clinical trial supporting the potential of its proprietary Cell Pouch System to provide a ‘functional cure’ for insulin-dependent diabetes. The updated data from the ongoing study being conducted by Piotr Witkowski, M.D., Ph.D. at the University of Chicago, were presented as an oral podium presentation at the American Diabetes Association (ADA) 82nd Scientific Sessions, held from June 3-7, 2022, at the Ernest N. Morial Convention Center in New Orleans, LA.

The presented data, from the Dr. Piotr Witkowski Laboratory at the University of Chicago, reviewed the six patients who lived with long-standing insulin-dependent type 1 diabetes (T1D) and hypoglycemia unawareness prior to study treatment who underwent both Cell Pouch implantation and islet transplantation. Graft function was measured by blood glucose, patient insulin usage, and C-peptide, a widely used measure of islet function. The first three patients achieved complete and sustained insulin independence. Three additional patients on study did not maintain optimal immunosuppression, which has now been resolved enabling those patients to receive further protocol-defined islet transplants.

Key findings from interim clinical update: • Surgical implantation of the Cell Pouch was found to be generally well tolerated with a favorable safety profile • All patients who had favorable immunosuppression achieved complete insulin independence o The first three transplanted patients presented positive serum C-peptide values confirming active insulin production after islet transplantation into the Sernova Cell Pouch o Supplemental marginal dose islet transplantation via the portal vein was sufficient to allow those three patients to achieve and maintain insulin independence for over 2 years, 6 months, and 3 months, respectively o Insulin independent patients have HbA1c in the normal range: 5.0, 5.2, and 5.2%, respectively

• Dr. Witkowski further optimized outcomes in the ongoing clinical trial: o Replacing patients’ own plasma with serum as the islet suspension medium o Decreasing the concentration of islet suspensions transplanted to Cell Pouch resulted in greater stimulated C-peptide o The Cell Pouch implantation procedure was optimized with two shorter incisions to minimize infection risk and enhance healing o Implementing a higher capacity Cell Pouch System, that has been developed by Sernova, will provide approximately 50% more volume to accommodate more islets at the optimal concentration for use in future implantation procedures

“Despite some advances in the diabetes space, insulin-dependent diabetes patients continue to require numerous injections daily, and for those with hypoglycemia unawareness, it can be increasingly life threatening. We are committed to developing a ‘functional cure’ to potentially free patients from the life-limiting burdens of this disease,” said Dr. Philip Toleikis, President and Chief Executive Officer of Sernova. “We are encouraged by the data demonstrating our Cell Pouch System has been well tolerated and multiple patients remain insulin independent. We remain on track to further dose the three aforementioned subjects and to implement the higher capacity Cell Pouch System in the next implanted patients.”

The incidence of T1D in the U.S. (in ages 0 to 64 years) is estimated to be 64,000 cases annually, with a predicted prevalence of 5 million people by 2050 (1,2). The annual direct cost of healthcare expenditures and lost income from T1D has been estimated as $16 billion (3). Sernova’s Cell Pouch System is designed to address this vastly expanding need by providing a ‘functional cure’ for the millions of people afflicted by insulin-dependent diabetes worldwide. Sernova is also addressing the life-threatening complication of hypoglycemia unawareness (HU) in patients with T1D. HU is a person’s inability to recognize the symptoms of low blood sugar before it becomes severe enough to be incapacitating or even fatal. About 1 in 5 people with T1D report experiencing hypoglycemia unawareness (4).

Dr. Piotr Witkowski, Director of Pancreatic Islet Transplantation Program at University of Chicago and study Principal Investigator added, “The data coming out of the Cell Pouch and islet transplantation trial show incredible promise for insulin-dependent diabetes patients. I am excited about the potential impact on the field and look forward to seeing continued progression of the data from this trial.”

Sernova recently entered into a global strategic partnership with Evotec A.G., a Nasdaq listed biotechnology company, to develop an implantable off-the-shelf induced pluripotent stem cell (iPSC) -based beta cell replacement therapy, which will provide Sernova with an unlimited supply of insulin-producing cells, circumventing any potential future islet supply issues. Sernova is also working to eliminate the need for chronic immunosuppression with cell transplants by incorporating technology developed by Dr. Alice Tomei’s laboratory at the University of Miami, to protect cells from immune system recognition.

For more information on the ongoing clinical study, go to clinicaltrials.gov (NCT03513939).

1. Rogers MAM, Kim C, Banerjee T, Lee JM. Fluctuations in the incidence of type 1 diabetes in the United States from 2001 to 2015: a longitudinal study. BMC Med. 2017;15(1):199. Published 2017 Nov 8. doi:10.1186/s12916-017-0958-6

2. Dabelea D, Mayer-Davis EJ, Saydah S, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA. 2014;311(17):1778-1786. doi:10.1001/jama.2014.3201

3. American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917-928. doi:10.2337/dci18-0007

4. Reno CM, Litvin M, Clark AL, Fisher SJ. Defective counterregulation and hypoglycemia unawareness in diabetes: mechanisms and emerging treatments. Endocrinol Metab Clin North Am. 2013;42(1):15-38. doi:10.1016/j.ecl.2012.11.005

ABOUT SERNOVA CORP. AND THE CELL POUCH SYSTEM PLATFORM FOR CELL THERAPY

Sernova Corp is a clinical-stage biotechnology company that is developing regenerative medicine therapeutic technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders like hemophilia A. Sernova is currently focused on finding a ‘functional cure’ for insulin-dependent diabetes with its lead asset, the Cell-Pouch SystemTM, a novel implantable and scalable medical device which forms a natural environment in the body for long-term survival and function of therapeutic cells that release necessary proteins or factors missing from the body to treat chronic diseases. Sernova’s Cell Pouch System has already shown it can potentially provide a ‘functional cure’ to people with type 1 diabetes in an ongoing Phase I/II study at the University of Chicago. Sernova is also working on technology with the University of Miami to cloak the implant from the immune system, to eliminate the need for immunosuppressives to protect the cells from immune system attack. In May 2022, Sernova and Evotec entered into a global strategic partnership to develop an implantable off-the-shelf iPSC-based (induced pluripotent stem cells) beta cell replacement therapy. This partnership provides Sernova an unlimited supply of insulin-producing cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2). Sernova is also gearing up to be in the clinic in two programs that utilize its Cell Pouch System – an implantable cell therapy for benign thyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral factor 8 gene therapy for hemophilia A.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Corporate: Christopher Barnes VP, Investor Relations Sernova Corp. christopher.barnes@sernova.com Tel: 519-902-7923 www.sernova.com

Investors: Corey Davis, Ph.D. LifeSci Advisors, LLC cdavis@lifesciadvisors.com Tel: 212-915-2577

Media: Elizabeth Miller, M.D. LifeSci Communications emiller@lifescicomms.com

FORWARD-LOOKING INFORMATION This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and/or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedar.com for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - June 01, 2022 1 June, 2022

SERNOVA SHARES TO COMMENCE TRADING ON TSX ON JUNE 2, 2022


June 1, 2022 6:00 a.m. EDT

London, Ontario – June 1, 2022 – Sernova Corp. (TSX-V:SVA; OTCQB:SEOVF; FSE/XETRA:PSH), a clinical- stage company and leader in regenerative medicine cell therapeutics, is pleased to announce that its common shares have been approved for listing on the Toronto Stock Exchange (the "TSX") and will commence trading on the TSX at the opening of market on June 2, 2022. Concurrent with the TSX listing, the common shares of the Company will be delisted from the TSX Venture Exchange.

Shareholders are not required to exchange their share certificates or take any other action in connection with the TSX listing, as there will be no change in the trading symbol or CUSIP for the common shares. The Company will continue to trade its common shares on the OTCQB market in the United States under the symbol "SEOVF", and the Frankfurt exchange under the symbol "PSH".

ABOUT SERNOVA CORP. AND THE CELL POUCH SYSTEM™ PLATFORM FOR CELL THERAPY Sernova Corp. is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e., human donor cells, corrected human cells and stem-cell derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body.

The Cell Pouch™ is a proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. After implantation, the device incorporates with tissue, forming highly vascularized, native tissue chambers for the transplantation and function of therapeutic cells, that release proteins and hormones as required to treat disease.

The Cell Pouch along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans in a Canadian first-in-human study. Sernova is currently conducting a Phase 1/2 clinical trial study at the University of Chicago. Encouraging interim results have been presented at several international scientific conferences.

For more information, please visit www.sernova.com

For further information contact:

Corporate and Investors: Sernova Corp. Christopher Barnes Tel: (519) 858-5126 christopher.barnes@sernova.com www.sernova.com

Investors: Corey Davis, Ph.D. LifeSci Advisors, LLC cdavis@lifesciadvisors.com Tel: 212-915-2577

Media: Elizabeth Miller, MD LifeSci Communications emiller@lifescicomms.com

Neither the TSXV nor the TSX accepts responsibility for the adequacy or accuracy of this news release.

FORWARD-LOOKING INFORMATION This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials, and the development of new technologies, cell therapy solutions and or products. The information disclosed represents results from one patient and may not be representative of all study patients or of the final study results. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.



Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - May 24, 2022 24 May, 2022

Sernova Receives Conditional Approval to Up-list to the Toronto Stock Exchange


London, Ontario – May 24, 2022 – Sernova Corp. (TSX-V:SVA; OTCQB:SEOVF; FSE/XETRA:PSH), a clinical- stage company and leader in regenerative medicine cell therapeutics, is pleased to announce that it has received conditional approval to list its common shares on the Toronto Stock Exchange (the "TSX") and move off of the TSX Venture Exchange ("TSXV").

Final approval of the listing is subject to the Company meeting certain customary conditions required by the TSX. The company will issue a press release once the TSX confirms the date when trading of Sernova’s common shares is expected to commence on the TSX. Upon completion of the final listing requirements, Sernova’s common shares will be delisted from the TSXV.

Dr. Philip Toleikis, President and CEO of Sernova Corp commented, “Moving onto the Toronto Stock Exchange represents a milestone achievement in our evolution as an emerging regenerative medicine company. Up- listing will provide enhanced liquidity and bring new visibility and investors into the company as we advance our therapeutic cell therapy platform with the goal to provide ‘functional cures’ for multiple diseases including type one diabetes, hemophilia and thyroid disease.”

Shareholders are not required to exchange their share certificates or take any other action in connection with the TSX listing, as there will be no change in the trading symbol or CUSIP for the common shares. The Company will continue to trade its common shares on the OTCQB market in the United States under the symbol "SEOVF", and the Frankfurt exchange under the symbol "PSH".

ABOUT SERNOVA CORP. AND THE CELL POUCH SYSTEM™ PLATFORM FOR CELL THERAPY

Sernova Corp. is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e., human donor cells, corrected human cells and stem-cell derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body.

The Cell Pouch™ is a proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. After implantation, the device incorporates with tissue, forming highly vascularized, native tissue chambers for the transplantation and function of therapeutic cells, that release proteins and hormones as required to treat disease.

The Cell Pouch along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans in a Canadian first-in-human study. Sernova is currently conducting a Phase 1/2 clinical trial study at the University of Chicago. Encouraging interim results have been presented at several international scientific conferences.

For more information, please visit www.sernova.com

For further information contact:

Corporate and Investors: Sernova Corp. Christopher Barnes Tel: (519) 858-5126 christopher.barnes@sernova.com www.sernova.com

Investors: Corey Davis, Ph.D. LifeSci Advisors, LLC cdavis@lifesciadvisors.com Tel: 212-915-2577

Media: Elizabeth Miller, MD LifeSci Communications emiller@lifescicomms.com

Neither the TSXV nor the TSX accepts responsibility for the adequacy or accuracy of this news release.

FORWARD-LOOKING INFORMATION This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials, and the development of new technologies, cell therapy solutions and or products. The information disclosed represents results from one patient and may not be representative of all study patients or of the final study results. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - May 17, 2022 17 May, 2022

Sernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based Beta Cell Replacement Therapy to Develop and Commercialize a 'Functional Cure' for Diabetes


• Partnership Leverages Sernova’s Proprietary Cell Pouch System™ with Evotec’s iPSC-Based Insulin- Producing Beta Cells • Partners to Develop and Commercialize an Off-The-Shelf Cell Replacement Therapy for Treatment of Patients with Insulin-Dependent Diabetes • Evotec to Make Strategic Equity Investment of CAD $27 M / €20 M in Sernova • Sernova / Evotec Joint Conference Call and Webcast at 8:30 am EDT May 17, 2022

LONDON, ONTARIO – May 17, 2022 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE/XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, and Evotec SE (FSE: EVT; NASDAQ: EVO), a global pharmaceutical and life science company, and leading developer of iPSC cell technologies for therapeutic applications, are pleased to announce an exclusive global strategic partnership to develop a best-in-class cell therapy treatment for people living with insulin-dependent diabetes. The two Companies will combine and leverage their respective technologies and scientific expertise to develop an implantable iPSC-based (induced pluripotent stem cells) beta cell replacement therapy to provide an unlimited insulin-producing cell source to treat patients with insulin-dependent diabetes.

The collaboration agreement is a transformative partnership that combines Sernova’s Cell Pouch System technologies, which has demonstrated Phase 1/2 clinical proof-of-concept using human donor islets, with Evotec’s iPSC-based beta cells. Incorporating Evotec’s insulin-producing, ethically-derived beta cells within Sernova’s Cell Pouch platform creates the potential to provide a ‘functional cure’ for millions of people suffering from diabetes using a cGMP controlled and scalable off-the-shelf product.

With its long-standing beta cell development program, Evotec has demonstrated the ability to reliably produce an unlimited supply of high quality, stable, human iPSC-derived beta cells using its proprietary process for producing islet-like clusters in a quality-controlled scalable bioreactor process. These islet-like clusters have now been proven to be functionally equivalent to primary human islets in their ability to normalize blood glucose using in vivo models of type 1 diabetes (T1D).

The partnership provides Sernova a global exclusive option to license Evotec’s iPSC-based beta cells for use in treating both type 1 and type 2 diabetes. In addition to entering into the collaboration agreement, Evotec has made a strategic equity investment of €15M and will make a further investment of €5M. Specifically, concurrently with the entering into the collaboration agreement, Evotec acquired a total of 12,944,904 common shares at a price of CAD $1.57 per share for gross proceeds to Sernova of $20,323,500. In addition, pursuant to an unconditional purchase warrant, Evotec will acquire, on or before August 31, 2022, a further 2,709,800 common shares at a price of CAD$2.50 per share for gross proceeds of $6,774,500. All of the securities issued to Evotec are subject to a four month hold period.

Further to the collaboration and Evotec’s strategic equity investment, Dr. Cord Dohrmann, Chief Scientific Officer of Evotec will join Sernova’s Board of Directors.

Dr. Philip Toleikis, President, and Chief Executive Officer of Sernova, commented, “In tandem with our current clinical islet cell program, Sernova entered into multiple pharmaceutical research collaborations to identify the highest quality and most compatible iPSC cell technology, and validate the cells preclinically within our Cell Pouch System. Evotec is an iPSC powerhouse having dedicated many years and substantial resources to developing high quality and stable stem cell technologies for multiple therapeutic applications. In every sense, both as a global strategic partner and as an iPSC expert, Evotec has exceeded all our expectations and Dr. Dohrmann’s appointment to Sernova’s Board adds significant regenerative medicine depth and cell therapy expertise. Today’s announcement of this joint iPSC beta-cell partnership completes the three pillars of our diabetes cell therapy platform. Alongside our clinically validated Cell Pouch System and recently acquired conformal coating immune protection technology, this now establishes a total regenerative medicine cell therapy solution for insulin-dependent diabetes.”

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented, “We searched long and hard for the right partner. Sernova clearly ticks all boxes with their clinically validated Cell Pouch™ technology, which fits perfectly to Evotec’s iPSC-based beta cells. Together we will progress a highly differentiated first-in-class beta cell therapy into clinical development with the common goal to bring a truly transformative therapy to insulin- dependent diabetic patients. The synergies of Evotec’s and Sernova’s technologies puts Sernova in position to become the world’s leader in beta cell replacement therapy. Our equity investment underlines our strategic interest in this collaboration with Sernova. I am very much looking forward to collaborating with Sernova on the project as well as contributing to their Board of Directors.”

Sernova has acquired an option for an exclusive global license to Evotec’s Induced Pluripotent Stem Cell (iPSC)-based Beta cells to treat patients with insulin-dependent diabetes. From an operational perspective, the preclinical development program(s) will be jointly funded by Sernova and Evotec until IND acceptance. Sernova has the right to exercise its option for an exclusive global license upon IND filing. Evotec will contribute its cell manufacturing capabilities through research, development and product commercialization and will decide in the future on the joint funding of clinical development. Upon commercialization, there will be a profit-sharing arrangement between the two companies, with the split being dependent on Evotec’s participation in funding the clinical development program.

Joint Sernova / Evotec Conference Call and Webcast Details:

Date: Tuesday, May 17, 2022 Time: 8:30 am EDT US Toll Free: 1-877-704-4453 International: 1-201-389-0920 Conference ID: 13730121 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1550130&tp_key=3de87cce1d

A simultaneous slide presentation will be available via the above webcast link.

ABOUT SERNOVA CORP AND THE CELL POUCH SYSTEM CELL THERAPY PLATFORM

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e., human donor cells, corrected human cells and stem-cell derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body.

The Cell Pouch, as part of the Cell Pouch System, is a proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. After implantation, the device incorporates with tissue, forming highly vascularized, native tissue chambers for the transplantation and function of therapeutic cells, that release proteins and hormones as required to treat disease.

The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans in a Canadian first-in-human study. Sernova is currently conducting a Phase 1/2 clinical trial study at the University of Chicago. Encouraging interim results have been presented at several international scientific conferences. For more information, please visit www.sernova.com

ABOUT EVOTEC AND iPSC

Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The iPSC technology was pioneered by Shinya Yamanaka’s lab in Kyoto, Japan, who showed in 2006 that the introduction of four specific genes encoding transcription factors could convert adult cells into pluripotent stem cells. He was awarded the 2012 Nobel Prize along with Sir John Gurdon “for the discovery that mature cells can be reprogrammed to become pluripotent”. Pluripotent stem cells hold great promise in the field of regenerative medicine. Because they can propagate indefinitely, as well as give rise to every other cell type in the body (such as neurons, heart, pancreatic and liver cells), they represent a single source of cells that could be used to replace those lost to damage or disease.

Evotec has built an industrialised iPSC infrastructure that represents one of the largest and most sophisticated iPSC platforms in the industry. Evotec’s iPSC platform has been developed over the last years with the goal to industrialise iPSC-based drug screening in terms of throughput, reproducibility and robustness to reach the highest industrial standards, and to use iPSC-based cells in cell therapy approaches via the Company’s proprietary EVOcells platform.

For further information contact:

Corporate and Investors:

Sernova Corp Christopher Barnes Tel: (519) 858-5126 christopher.barnes@sernova.com www.sernova.com

Investors:

Corey Davis, Ph.D. LifeSci Advisors, LLC cdavis@lifesciadvisors.com Tel: 212-915-2577

Media:

Elizabeth Miller, MD LifeSci Communications emiller@lifescicomms.com

FORWARD-LOOKING INFORMATION This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials, and the development of new technologies, cell therapy solutions and or products. The information disclosed represents results from one patient and may not be representative of all study patients or of the final study results. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - May 09, 2022 9 May, 2022

Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation at American Diabetes Association 82nd Scientific Sessions 2022


LONDON, ONTARIO – May 9, 2022 – Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage cell therapy therapeutics company focused on developing a potential ‘functional cure’ for type 1 diabetes (T1D) and other chronic diseases, is pleased to announce that that an abstract has been selected for an oral podium presentation at the upcoming American Diabetes Association (ADA) 82nd Scientific Sessions, to be held from June 3-7, 2022, at the Ernest N. Morial Convention Center in New Orleans, LA.

Abstract 306-OR: Modified Approach for Improved Islet Allotransplantation into Prevascularized Sernova Cell PouchTM Device: Preliminary Results of the Phase I/II Clinical Trial at University of Chicago

Abstract Session: Islet Transplantation —Basic Science Session Date/Time: Monday, June 6, 2022 at 2:15 PM – 4:15 PM CT Presentation Time: 3:15-3:30 PM CT Authors: Bachul PJ, Perez-Guetierrez A, Ling-jia Wang, Golab K, Basto L, Perea L, Tibudan M, Braden J, Thomas C, Philipson L, Barth R, Fung JJ, Witkowski P

Sernova will disclose additional information about the presentation at the time of the conference in alignment with the American Diabetes Association’s abstract embargo policies.

ABOUT SERNOVA

Sernova is developing regenerative medicine cell therapeutic solutions using a medical device (Cell Pouch) and immune protected therapeutic cells / tissues (i.e. human donor cells, corrected human cells and stem cell- derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through cellular production of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.

ABOUT SERNOVA’S CELL POUCH SYSTEM CELL THERAPY PLATFORM

The Cell Pouch, as part of the Cell Pouch System, is a novel, proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. After implantation, the device incorporates with tissue, forming highly vascularized, native tissue chambers for the transplantation and function of therapeutic cells, that release proteins and hormones as required to treat disease.

The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans in a Canadian first-in-human study. Sernova is currently conducting a Phase 1/2 clinical trial study at the University of Chicago. Encouraging interim results have been presented at several international scientific conferences.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Corporate: Christopher Barnes VP, Investor Relations Sernova Corp. christopher.barnes@sernova.com Tel: 519-902-7923 www.sernova.com

Investors: Corey Davis, Ph.D. LifeSci Advisors, LLC cdavis@lifesciadvisors.com Tel: 212-915-2577

Media: Elizabeth Miller, M.D. LifeSci Communications emiller@lifescicomms.com



FORWARD-LOOKING INFORMATION This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and/or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedar.com for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - May 05, 2022 5 May, 2022

Sernova to Participate in Multiple U.S. Healthcare Investor Conferences


Sernova Engages Leading U.S.-Based Healthcare Communications Firm to Broaden Awareness of Potential ‘Functional Cure’ Technology for Type 1 Diabetes

LONDON, ONTARIO – May 5, 2022 – Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical stage regenerative medicine company focused on developing a potential ‘functional cure’ for type 1 diabetes (T1D) and other chronic diseases including hemophilia A and thyroid disease, today announced that the company will be participating in several upcoming U.S. healthcare industry and investor conferences. Conference details are provided below.

The Company is also pleased to announce it has engaged New York-based LifeSci Communications, a global life science and medical technologies-focused communications and marketing agency. LifeSci Communications will assist Sernova to expand and elevate its profile through strategic communications and public relations. Sernova is also working with affiliate LifeSci Advisors LLC, a leading investor relations consultancy firm serving life science companies, providing institutional investor communications and capital markets outreach services in support of the Company’s U.S. capital markets objectives.

“With multiple collaborations advancing across our pipeline and growing interest in our best-in-class cell therapy therapeutic solution platform - consisting of immune protected therapeutic cells and our proprietary Cell Pouch™ medical device - as a potential ‘functional cure’ for multiple patient populations, the timing is right to drive awareness of our unique cell therapy proposition and unprecedented clinical results including the demonstration of continuous insulin independence for over two years now in our most advanced Phase 1/2 T1D study patient, in contrast to the clinical setbacks of several of our peer companies,” commented Dr. Philip Toleikis, President & CEO of Sernova.

UPCOMING U.S. HEALTHCARE INDUSTRY AND INSTITUTIONAL INVESTOR PRESENTATIONS

Event: Roth Capital’s Canada Corporate Access Day Date: May 17, 2022 Format: Corporate presentation and 1x1 meetings with institutional investors Location: New York, NY Event: H.C. Wainwright Global Life Sciences Conference Date: May 24-25, 2022 Format: Corporate presentation and 1x1 meetings with institutional investors Location: Miami Beach, FL Event: Truist Securities Cell Therapy Symposium Date: June 28, 2022 Format: Panel expert and discussions Location: New York, NY

ABOUT SERNOVA Sernova is developing regenerative medicine cell therapeutic solutions using a medical device (Cell Pouch) and immune protected therapeutic cells / tissues (i.e. human donor cells, corrected human cells and stem cell- derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through cellular production of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com. ABOUT SERNOVA’S CELL POUCH SYSTEM CELL THERAPY PLATFORM The Cell Pouch, as part of the Cell Pouch System, is a novel, proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. After implantation, the device incorporates with tissue, forming highly vascularized, native tissue chambers for the transplantation and function of therapeutic cells, that release proteins and hormones as required to treat disease. The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans in a Canadian first-in-human study. Sernova is currently conducting a Phase 1/2 clinical trial study at the University of Chicago. Encouraging interim results have been presented at several international scientific conferences. FOR FURTHER INFORMATION, PLEASE CONTACT: Investors and Analysts Christopher Barnes Corey Davis, Ph.D. VP, Investor Relations Managing Director Sernova Corp. LifeSci Advisors, LLC christopher.barnes@sernova.com cdavis@lifesciadvisors.com Tel: 519-902-7923 Tel: 212-915-2577 www.sernova.com Media Elizabeth Miller, M.D. LifeSci Communications emiller@lifescicomms.com FORWARD-LOOKING INFORMATION This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and/or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to complete collaboration activities; ability to secure collaboration arrangements from its collaboration activities; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedar.com for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - April 29, 2022 29 April, 2022

Sernova Announces 2022 Annual General Meeting Results


LONDON, ONTARIO – April 29, 2022 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinical stage regenerative medicine company focused on developing a potential ‘functional cure’ for type 1 diabetes (T1D) and other chronic diseases, is pleased to announce results from its Annual General Meeting of Shareholders (the “AGM”) held virtually via live audio webcast, on April 28, 2022. Shareholders voted overwhelmingly in favour of all management resolutions proposed in the Company’s Information Circular.

The following resolutions were proposed and approved at the AGM: • The re-election of the following directors for the ensuing year: Frank Holler, James Parsons, Jeffrey Bacha, Deborah Brown, Dr. Mohammad Azab and Dr. Philip Toleikis. • The appointment of Davidson & Company LLP, as auditors of the Company until the next annual meeting and the authorization of the directors of the Company to fix the remuneration to be paid to the auditors.

“I sincerely appreciate our shareholders ongoing support for Sernova. The Board and management are very excited about the immediate and long-term prospects of the Company as we expand our therapeutic applications, broaden our capital markets following and execute on a number of strategic initiatives,” said Dr. Philip Toleikis, President & CEO of Sernova Corp.

Management’s corporate update to shareholders will be available on Sernova’s website next week at www.sernova.com.

For further information contact:

Sernova Corp Christopher Barnes Tel: (519) 858-5126 christopher.barnes@sernova.com www.sernova.com

Corey Davis, Ph.D. LifeScience Advisors, LLC cdavis@lifesciadvisors.com Tel: 212-915-2577

ABOUT SERNOVA

Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e., human donor cells, corrected human cells and stem-cell derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

ABOUT SERNOVA’S CELL POUCH

The Cell Pouch is a novel, proprietary, scalable, implantable macro-encapsulation device designed for the long- term survival and function of therapeutic cells. The device is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells which then release proteins and hormones as required to treat disease. The device along with therapeutic cells has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans.

FORWARD-LOOKING INFORMATION This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials. The information disclosed represents results from one patient and may not be representative of all study patients or of the final study results. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.



Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - March 17, 2022 17 March, 2022

Data Safety Monitoring Board Recommends Continuation of Phase 1/2 Clinical Trial with Sernova’s Cell Pouch System™ in Patients with Type-1 Diabetes


Confirms Ongoing Safety and Tolerability of Sernova’s Cell Pouch

March 17, 2022 10:00 a.m. EDT

LONDON, ONTARIO – March 17, 2022 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinical- stage company and leader in regenerative medicine cell therapeutics, is pleased to announce that the Data Safety Monitoring Board ("DSMB") has completed the third annual review of Sernova’s ongoing Phase 1/2 clinical study “Safety, Tolerability and Efficacy Study of Sernova’s Cell Pouch for Clinical Islet Transplantation” in patients with Type-1 Diabetes (T1D) who suffer from hypoglycemia unawareness and severe hypoglycemic events.

In their assessment, the DSMB recommended that the clinical study should continue according to the study plan.

The DSMB is an independent committee of clinical experts who review the accumulated trial data to evaluate patient safety and ensure the integrity of the study data.

“This recommendation from the DSMB affirms our understanding of the safety of Cell Pouch in this patient population transplanted with human donor islets. We look forward to sharing updates from the study through upcoming conference presentations by Dr. Piotr Witkowski, the trial Principal Investigator.” said Dr. Philip Toleikis, President & CEO of Sernova Corp.

For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more information on enrollment and recruitment details please visit www.pwitkowski.org/sernova.

ABOUT HYPOGLYCEMIA UNAWARENESS Hypoglycemia unawareness is a person’s inability to recognize the symptoms of low blood sugar before they become severe enough to be incapacitating or even fatal, which may occur when blood glucose levels are below 3.0 mmol/L. It is estimated that approximately 15% of people with T1D, or approximately 240,000 people, are affected by hypoglycemia unawareness in the US alone. Severe symptoms of low blood sugar include confusion, slurred speech, impaired motor coordination and personality changes. Individuals experiencing a severe hypoglycemic event can lose their ability for self-care and self-control, requiring urgent intervention from another person to prevent loss of consciousness, seizure, coma, or death. After a person has had a first hypoglycemia unawareness episode, more are likely to occur.

ABOUT SERNOVA Sernova is developing regenerative medicine cell therapeutic solutions using a medical device (Cell Pouch) and immune protected therapeutic cells / tissues (i.e. human donor cells, corrected human cells and stem cell- derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through cellular production of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.

ABOUT SERNOVA’S CELL POUCH SYSTEM CELL THERAPY PLATFORM The Cell Pouch, as part of the Cell Pouch System, is a novel, proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. After implantation, the device incorporates with tissue, forming highly vascularized, native tissue chambers for the transplantation and function of therapeutic cells, that release proteins and hormones as required to treat disease. The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans in a Canadian first-in-human study. Sernova is currently conducting a Phase 1/2 clinical trial study at the University of Chicago. Positive initial results have been presented at several international scientific conferences.

FOR FURTHER INFORMATION, PLEASE CONTACT: Christopher Barnes VP, Investor Relations Sernova Corp. christopher.barnes@sernova.com Tel: 519-902-7923 www.sernova.com

Corey Davis, Ph.D. LifeScience Advisors, LLC cdavis@lifesciadvisors.com Tel: 212-915-2577

FORWARD-LOOKING INFORMATION

This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and/or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedar.com for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - February 24, 2022 24 February, 2022

Sernova Corp Ranks Among Top 50 Performing Companies on the 2022 TSX Venture List


Sernova awarded top performer status for two years standing

February 24, 2022 7:30 a.m. EST

LONDON, ONTARIO – February 24, 2022 – Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage regenerative medicine and cell therapy therapeutics company focused on developing a potential ‘functional cure’ for type 1 diabetes (T1D) and other chronic diseases, is pleased to announce that that it has been named as one of the top 50 performers on the TSX Venture Exchange.

The 2022 TSX Venture Top 50 is a ranking of top performers on the TSX Venture Exchange over the last year based on three equally weighted criteria: share price appreciation, average trading volume and market capitalization growth.

“We are honored by the TSX Venture Exchange recognition of Sernova as a 2022 Top 50 recipient company. Being awarded this title two years in a row is strong validation of our persistent dedication to increasing shareholder value as we continue to deliver on our strategic plan to build a leadership position in the regenerative medicine cell therapy therapeutics field. In 2022, we look forward to driving continued success through, evolving our clinical programs, further developing our pharmaceutical partnerships and by advancing our capital market initiatives,” said Dr. Philip Toleikis, Chief Executive Officer of Sernova.

As part of the award, the TSX Venture Exchange sponsored a Q&A highlight interview with Dr. Toleikis. To view the video, please https://share.vidyard.com/watch/dsfSgoQyYi87x8pj8oUEz6 and for the complete list of 2022 TSX Venture 50 companies.

ABOUT SERNOVA Sernova is developing regenerative medicine therapeutic solutions using a medical device (Cell Pouch) and immune protected therapeutic cells / tissues (i.e. human donor cells, corrected human cells and stem cell- derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through cellular production of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.

ABOUT SERNOVA’S CELL POUCH SYSTEM

The Cell Pouch, as part of the Cell Pouch System, is a novel, proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. The device upon implantation is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells, which then release proteins and hormones as required to treat disease.

The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans in a Canadian first-in-human study. Sernova is currently conducting a Phase I/II study at the University of Chicago. Positive initial results have been presented at several international scientific conferences.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Christopher Barnes VP, Investor Relations Sernova Corp. christopher.barnes@sernova.com Tel: 519-902-7923 www.sernova.com

Corey Davis, Ph.D. LifeSci Advisors, LLC cdavis@lifesciadvisors.com Tel: 212-915-2577

FORWARD-LOOKING INFORMATION This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and/or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedar.com for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.